Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -393.39% is 14% below its 3-year average of -343.91%, around the middle of its 3-year range (-826.04%–-98.42%).
74.39% below its 12-month average of -225.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -93.60%.
RETURN ON ASSETS (ROA)
-393.39%
RETURN ON ASSETS (ROA) AVG TTM
-225.59%
RETURN ON ASSETS (ROA) AVG 3Y
-343.91%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-74.39%
CURRENT VS 3Y AVG
-14.39%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.01%
median of 598 covered companies
CURRENT VS SECTOR MEDIAN
-1256.28%
vs the sector median at left
Actuate Therapeutics Inc
Market Cap
$19.59M
Return on Assets (ROA)
-393.39%
TTM Avg
-225.59%
3Y Avg
-343.91%
5Y Avg
N/A
Market Cap
$19.18M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$18.92M
Return on Assets (ROA)
-64.55%
TTM Avg
-0.45%
3Y Avg
-55.72%
5Y Avg
-45.67%
Market Cap
$19.96M
Return on Assets (ROA)
-548.74%
TTM Avg
-346.44%
3Y Avg
-242.08%
5Y Avg
-167.09%
Market Cap
$20.50M
Return on Assets (ROA)
-228.73%
TTM Avg
-145.44%
3Y Avg
-152.25%
5Y Avg
-187.73%
Market Cap
$17.34M
Return on Assets (ROA)
-59.70%
TTM Avg
-56.25%
3Y Avg
-61.89%
5Y Avg
-61.99%
Market Cap
$17.07M
Return on Assets (ROA)
-49.72%
TTM Avg
-28.29%
3Y Avg
-39.08%
5Y Avg
-40.04%
Market Cap
$16.58M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$22.43M
Return on Assets (ROA)
-13.57%
TTM Avg
-12.25%
3Y Avg
-12.55%
5Y Avg
-25.19%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Actuate Therapeutics Inc (ACTU) | $19.59M | -393.39% | -225.59% | -343.91% | N/A |
| Cosmos Health Inc. (COSM)vs › | $19.18M | -39.68% | -29.52% | -26.86% | -20.28% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.92M | -64.55% | -0.45% | -55.72% | -45.67% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $19.96M | -548.74% | -346.44% | -242.08% | -167.09% |
| Modular Medical, Inc. (MODD)vs › | $20.50M | -228.73% | -145.44% | -152.25% | -187.73% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.34M | -59.70% | -56.25% | -61.89% | -61.99% |
| Lipocine Inc. (LPCN)vs › | $17.07M | -49.72% | -28.29% | -39.08% | -40.04% |
| Dyadic International, Inc. (DYAI)vs › | $16.58M | -116.60% | -66.28% | -71.56% | -63.10% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.43M | -13.57% | -12.25% | -12.55% | -25.19% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | -67.58% | -90.98% | -83.38% | -70.12% |
ROA
-393.4%
ROE
-2067.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -158.36% |
| 2024-12-31 | -292.81% |
| 2023-12-31 | -826.04% |
| 2022-12-31 | -98.42% |
